A Safety Tolerance and Experimental Hyperalgesia Study of Oral NGX426 in Healthy Male Voluneteers

Phase 1

Completed

• Conditions: Healthy; Hyperalgesia
• Interventions: Drug: Placebo; Drug: Oral NGX426 (Powder in solution)

• Registration Number: NCT00832546
• Lead Sponsor: TorreyPines Therapeutics

Brief Summary

The purpose of this study is to determine the effects of NGX426 on intradermal capsaicin induced pain in hyperalgesia.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-05
• Primary Completion: 2008-09
• Study Completion: 2008-09
• Status Verified: 2009-01
• Study First Submitted: 2009-01-28
• Study First Submitted QC: 2009-01-29
• Last Update Submitted: 2009-01-29
• Study First Posted: 2009-01-30
• Last Update Posted: 2009-01-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 18

Inclusion Criteria

• Healthy males, age 21-55

Exclusion Criteria

• Allergy to study drug

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
1	Placebo	Placebo
2	Oral NGX426 (Powder in solution)	Powder in solution
3	Oral NGX426 (Powder in solution)	-

Trial Locations

Locations (1)

University of California; 🇺🇸 San Diego, California, United States